Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026
Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026
Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Deals

Easton Pharma’s Oxazepam Receives NMPA Approval and Partners with Nhwa

Fineline Cube Jun 5, 2025

Chengdu-based Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that its oxazepam has received marketing approval...

Company Drug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease

Fineline Cube Jun 4, 2025

France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD)...

Company Drug

Ascletis Pharma’s Denifanstat Meets Phase III Endpoints in Severe Acne Trial

Fineline Cube Jun 4, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the Phase III clinical study of its...

Company Deals Drug

Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products

Fineline Cube Jun 4, 2025

US-based Eli Lilly & Co. (NYSE: LLY) entered into a collaboration and licensing agreement with...

Company Drug

CirCode Biomed’s Circular RNA Drug HM2002 Approved for US Clinical Trials

Fineline Cube Jun 4, 2025

China-based Shanghai CirCode Biomed Co. Ltd., a specialist in circular RNA therapies, announced that its...

Company Medical Device

Bio-heart Launches Iberis Renal Ablation System at OCC 2025

Fineline Cube Jun 4, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) hosted the product launch of its...

Company Deals

BioAge Labs Partners with JiKang for APJ Agonist Nanobody License

Fineline Cube Jun 4, 2025

US-based biotech BioAge Labs, Inc. announced an option agreement with China’s JiKang Therapeutics, potentially securing...

Company Drug

Bayer’s Nubeqa Gets FDA Approval for mHSPC Treatment

Fineline Cube Jun 4, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration...

Company Deals

Sainte Nutritional Files for IPO in Hong Kong as FSMP Pioneer

Fineline Cube Jun 4, 2025

Sainte Nutritional Inc., China’s leading provider of Food for Special Medical Purpose (FSMP), has filed...

Company Drug

Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025

Fineline Cube Jun 4, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented the results of the Phase III CAMPASS study...

Company Deals

Harbin Gloria Partners with Eisai to Promote Methycobal in China

Fineline Cube Jun 4, 2025

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has entered into a market promotion service...

Company Drug

Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler

Fineline Cube Jun 4, 2025

Beijing-based Lepu Medical Technology (SHE: 300003), a provider of cardiovascular disease solutions, announced that its...

Company Drug

JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025

Fineline Cube Jun 4, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...

Company Drug

Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC

Fineline Cube Jun 4, 2025

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group...

Company Medical Device Policy / Regulatory

EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years

Fineline Cube Jun 4, 2025

China Central Television (CCTV) reported that EU member states have voted under the International Procurement...

Company Drug

Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025

Fineline Cube Jun 4, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) presented 5-year follow-up data from the CARTITUDE-1 study for...

Company Drug

EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen

Fineline Cube Jun 4, 2025

Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has...

Company Drug

Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer

Fineline Cube Jun 3, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced the enrollment of the first patient...

Company Deals

Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline

Fineline Cube Jun 3, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) announced plans to acquire US-based Blueprint Medicines Corporation for...

Company Deals

BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors

Fineline Cube Jun 3, 2025

Germany-based BioNTech SE (NASDAQ: BNTX) announced a strategic partnership with US major Bristol-Myers Squibb (BMS,...

Posts pagination

1 … 104 105 106 … 620

Recent updates

  • Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
  • Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
  • Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
  • GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
  • MediTrust Mabwell Insurance Ecosystem Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.